letter

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down ActivitiesVincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated…

4 weeks ago
FDA Issues Nyxoah an Approvable Letter for its Genio SystemFDA Issues Nyxoah an Approvable Letter for its Genio System

FDA Issues Nyxoah an Approvable Letter for its Genio System

INSIDE INFORMATIONREGULATED INFORMATION FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am…

1 month ago
President & CEO Letter to ShareholdersPresident & CEO Letter to Shareholders

President & CEO Letter to Shareholders

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, March 06, 2025…

2 months ago
NEXGEL Issues Letter to Shareholders and Provides Guidance for 2024 and 2025NEXGEL Issues Letter to Shareholders and Provides Guidance for 2024 and 2025

NEXGEL Issues Letter to Shareholders and Provides Guidance for 2024 and 2025

Management expects 2024 fourth quarter revenue of approximately $3.0 million and full year 2024 of approximately $8.6 million, representing growth…

3 months ago
TipMeFast, Inc. Announces Letter of Intent to Acquire Strategic Graphite and Gold Mine AssetsTipMeFast, Inc. Announces Letter of Intent to Acquire Strategic Graphite and Gold Mine Assets

TipMeFast, Inc. Announces Letter of Intent to Acquire Strategic Graphite and Gold Mine Assets

December 19, 2024 13:12 ET  | Source: Tipmefast, Inc. Irvine, Ca, Dec. 19, 2024 (GLOBE NEWSWIRE) -- TipMeFast, Inc. (“TipMeFast”…

5 months ago
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic GalactosemiaApplied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

November 27, 2024 16:10 ET | Source: Applied Therapeutics NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc.…

5 months ago
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseasesNordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases

Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases

HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE biomarker assay received a…

6 months ago
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseasesNordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases

Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases

HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE biomarker assay received a…

6 months ago
Data Storage Corporation Provides Letter to Shareholders Highlighting Recent Achievements within CloudFirst Technologies SubsidiaryData Storage Corporation Provides Letter to Shareholders Highlighting Recent Achievements within CloudFirst Technologies Subsidiary

Data Storage Corporation Provides Letter to Shareholders Highlighting Recent Achievements within CloudFirst Technologies Subsidiary

CloudFirst Continues Strong Financial Performance Along with Expansion into the United Kingdom and Operational Success Following Flagship Solutions Group Integration…

6 months ago